A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer

• Published in: Advances in therapy Vol. 32; no. 12; pp. 1237 - 1247
• Main Authors: Alvarado, Michael D., Prasad, Che, Rothney, Megan, Cherbavaz, Diana B., Sing, Amy P., Baehner, Frederick L., Svedman, Christer, Markopoulos, Christos J.
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.12.2015
• Subjects: Aged; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Cardiology; Endocrinology; Female; Gene Expression Profiling; Humans; Internal Medicine; Medicine; Medicine & Public Health; Middle Aged; Neoplasm Recurrence, Local - genetics; Neoplasm Recurrence, Local - pathology; Oncology; Original Research; Pharmacology/Toxicology; Prospective Studies; Receptors, Estrogen - metabolism; Rheumatology; Risk Assessment; PAM50; Adjuvant chemotherapy; DX; Recurrence Score; Oncology; Breast cancer; Prosigna, risk assessment; Onco; Oncotype DX

Introduction The 21-gene Recurrence Score ® assay (Onco type DX ® , Genomic Health, Inc.) is a validated predictor of recurrence risk/chemotherapy benefit in patients with estrogen receptor-positive (ER+) early-stage breast cancer treated with endocrine therapy. The Prosigna ® assay (NanoString Tech...